WallabyPhenox launches PROMISE MeVO trial
2026-08-14
WallabyPhenox is wasting no time. The company reports that its PROMISE study has already moved from concept to first enrollment, signaling that medium vessel occlusion stroke is now a front line research target rather than a niche concern.
At the center of this shift is PROMISE, an investigator initiated prospective study designed to track how acute ischemic strokes from medium vessel occlusion are handled within the first 24 hours of onset, a window defined by cerebral blood flow dynamics and infarct core evolution. The trial focuses on real world management patterns rather than a tightly scripted interventional protocol, giving clinicians and sponsors a closer look at current decision making under emergency conditions.
Indiana University Methodist Hospital anchors the opening phase, with the first subject enrolled under the direction of co leads Devi Patra and Ann Jones. Their site becomes an early data node in a study that will rely on standardized imaging, vessel segment classification, and outcome scales such as the modified Rankin Scale to map treatment choices against neurological recovery. For WallabyPhenox, early enrollment marks a practical step toward defining where MeVO care should sit between medical therapy and device based thrombectomy.
Loading...
